ReP USP - Resultado da busca

Artigo de periodico
Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations (2024)
Ponnaiah, Maharajah; Zakiev, Emile; Lhomme, Marie; Rached, Fabiana; Camont, Laurent; Serrano Junior, Carlos Vicente ; Santos Filho, Raul Dias dos ; Chapman, M. John; Orekhov, Alexander; Kontush, Anatol
Source: ATHEROSCLEROSIS PLUS. Unidade: FM
Subjects: LIPOPROTEÍNAS LDL, INFARTO DO MIOCÁRDIO, FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PONNAIAH, Maharajah et al. Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations. ATHEROSCLEROSIS PLUS, v. 55, p. 21-30, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58815. Acesso em: 16 nov. 2024.
APA
Ponnaiah, M., Zakiev, E., Lhomme, M., Rached, F., Camont, L., Serrano Junior, C. V., et al. (2024). Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations. ATHEROSCLEROSIS PLUS, 55, 21-30. doi:10.1016/j.athplu.2023.12.001
NLM
Ponnaiah M, Zakiev E, Lhomme M, Rached F, Camont L, Serrano Junior CV, Santos Filho RD dos, Chapman MJ, Orekhov A, Kontush A. Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations [Internet]. ATHEROSCLEROSIS PLUS. 2024 ; 55 21-30.[citado 2024 nov. 16 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58815
Vancouver
Ponnaiah M, Zakiev E, Lhomme M, Rached F, Camont L, Serrano Junior CV, Santos Filho RD dos, Chapman MJ, Orekhov A, Kontush A. Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations [Internet]. ATHEROSCLEROSIS PLUS. 2024 ; 55 21-30.[citado 2024 nov. 16 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58815
Artigo de periodico
Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis (2024)
Chapleau, Marianne; Joie, Renaud La; Yong, Keir; Agosta, Federica; Allen, Isabel Elaine; Apostolova, Liana; Best, John; Boon, Baayla D. C; Crutch, Sebastian; Grinberg, Lea Tenenholz
Source: Lancet neurology. Unidade: FM
Subjects: DOENÇA DE ALZHEIMER, COMPROMETIMENTO COGNITIVO LEVE, DEMÊNCIA, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHAPLEAU, Marianne et al. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis. Lancet neurology, v. 23, n. 2, p. 168-177, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/59027. Acesso em: 16 nov. 2024.
APA
Chapleau, M., Joie, R. L., Yong, K., Agosta, F., Allen, I. E., Apostolova, L., et al. (2024). Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis. Lancet neurology, 23( 2), 168-177. doi:10.1016/S1474-4422(23)00414-3
NLM
Chapleau M, Joie RL, Yong K, Agosta F, Allen IE, Apostolova L, Best J, Boon BDC, Crutch S, Grinberg LT. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis [Internet]. Lancet neurology. 2024 ; 23( 2): 168-177.[citado 2024 nov. 16 ] Available from: https://observatorio.fm.usp.br/handle/OPI/59027
Vancouver
Chapleau M, Joie RL, Yong K, Agosta F, Allen IE, Apostolova L, Best J, Boon BDC, Crutch S, Grinberg LT. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis [Internet]. Lancet neurology. 2024 ; 23( 2): 168-177.[citado 2024 nov. 16 ] Available from: https://observatorio.fm.usp.br/handle/OPI/59027
Artigo de periodico
Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction (2022)
Docherty, Kieran F; Ogunniyi, Modele O; Anand, Inder S; Desai, Akshay S; Diez, Mirta; Howlett, Jonathan G; Nicolau, Jose Carlos ; O'meara, Eileen; Verma, Subodh; Inzucchi, Silvio E
Source: Jacc-heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, FÁRMACOS SINTÉTICOS, MORTALIDADE HOSPITALAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, v. 10, n. 1, p. 52-64, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jchf.2021.08.006. Acesso em: 16 nov. 2024.
APA
Docherty, K. F., Ogunniyi, M. O., Anand, I. S., Desai, A. S., Diez, M., Howlett, J. G., et al. (2022). Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, 10( 1), 52-64. doi:10.1016/j.jchf.2021.08.006
NLM
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Vancouver
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Artigo de periodico
Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis (2022)
Wollenberg, Andreas; Marcoux, Danielle; I, Jonathan Silverberg; Aoki, Valeria ; Baselga, Eulalia; Zhang, Haixin; Levit, Noah A.; Taieb, Alain; Rossi, Ana B.
Source: Acta dermato-venereologica. Unidade: FM
Subjects: DERMATITE, CRIANÇAS, SINAIS E SINTOMAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WOLLENBERG, Andreas et al. Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis. Acta dermato-venereologica, v. 102, 2022Tradução . . Disponível em: https://doi.org/10.2340/actadv.v102.854. Acesso em: 16 nov. 2024.
APA
Wollenberg, A., Marcoux, D., I, J. S., Aoki, V., Baselga, E., Zhang, H., et al. (2022). Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis. Acta dermato-venereologica, 102. doi:10.2340/actadv.v102.854
NLM
Wollenberg A, Marcoux D, I JS, Aoki V, Baselga E, Zhang H, Levit NA, Taieb A, Rossi AB. Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis [Internet]. Acta dermato-venereologica. 2022 ; 102[citado 2024 nov. 16 ] Available from: https://doi.org/10.2340/actadv.v102.854
Vancouver
Wollenberg A, Marcoux D, I JS, Aoki V, Baselga E, Zhang H, Levit NA, Taieb A, Rossi AB. Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis [Internet]. Acta dermato-venereologica. 2022 ; 102[citado 2024 nov. 16 ] Available from: https://doi.org/10.2340/actadv.v102.854
Artigo de periodico
Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study (2021)
Arruda, Luisa Karla de Paula ; Yang, A. C.; Aoki, Valeria ; Criado, R. F. J.; Pires, M. C.; Lupi, O.; Fabricio, L. H. Z.; Richman, D.; Silvi, S.
Source: Journal of investigational allergology and clinical immunology. Unidades: FMRP, FM
Subjects: DERMATITE DE CONTATO, PREVALÊNCIA, QUALIDADE DE VIDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ARRUDA, Luisa Karla de Paula et al. Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study. Journal of investigational allergology and clinical immunology, v. 31, n. 3, p. 236-245, 2021Tradução . . Disponível em: https://doi.org/10.18176/jiaci.0478. Acesso em: 16 nov. 2024.
APA
Arruda, L. K. de P., Yang, A. C., Aoki, V., Criado, R. F. J., Pires, M. C., Lupi, O., et al. (2021). Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study. Journal of investigational allergology and clinical immunology, 31( 3), 236-245. doi:10.18176/jiaci.0478
NLM
Arruda LK de P, Yang AC, Aoki V, Criado RFJ, Pires MC, Lupi O, Fabricio LHZ, Richman D, Silvi S. Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study [Internet]. Journal of investigational allergology and clinical immunology. 2021 ; 31( 3): 236-245.[citado 2024 nov. 16 ] Available from: https://doi.org/10.18176/jiaci.0478
Vancouver
Arruda LK de P, Yang AC, Aoki V, Criado RFJ, Pires MC, Lupi O, Fabricio LHZ, Richman D, Silvi S. Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study [Internet]. Journal of investigational allergology and clinical immunology. 2021 ; 31( 3): 236-245.[citado 2024 nov. 16 ] Available from: https://doi.org/10.18176/jiaci.0478
Artigo de periodico
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia (2020)
Santos Filho, Raul Dias dos ; Stein, Evan A.; Hovingh, G. Kees; Blom, Dirk J; Soran, Handrean; Watts, Gerald F; Lopez, J. Antonio G; Bray, Sarah; Kurtz, Christopher E; Hamer, Andrew W
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, ANTICORPOS MONOCLONAIS, ENZIMAS PROTEOLÍTICAS, ANTIMETABÓLITOS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS FILHO, Raul Dias dos et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 75, n. 6, p. 565-574, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.12.020. Acesso em: 16 nov. 2024.
APA
Santos Filho, R. D. dos, Stein, E. A., Hovingh, G. K., Blom, D. J., Soran, H., Watts, G. F., et al. (2020). Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, 75( 6), 565-574. doi:10.1016/j.jacc.2019.12.020
NLM
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Vancouver
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Artigo de periodico
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes (2018)
Everett, Brendan M.; Nicolau, Jose C.; DONATH, Marc Y.; PRADHAN, Aruna D.; THUREN, Tom; PAIS, Prem; GLYNN, Robert J; LIBBY, Peter; RIDKER, Paul M.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTI-INFLAMATÓRIOS, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 16 nov. 2024.
APA
Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002
NLM
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Vancouver
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Artigo de periodico
Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial (2018)
Dillinger, Jean-Guillaume; Nicolau, Jose C.
Source: Circulation-cardiovascular interventions. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, ANGIOPLASTIA TRANSLUMINAL PERCUTÂNEA CORONÁRIA, TROMBOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DILLINGER, Jean-Guillaume e NICOLAU, Jose C. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. Circulation-cardiovascular interventions, v. 11, n. 6, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084. Acesso em: 16 nov. 2024.
APA
Dillinger, J. -G., & Nicolau, J. C. (2018). Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. Circulation-cardiovascular interventions, 11( 6). doi:10.1161/CIRCINTERVENTIONS.118.006084
NLM
Dillinger J-G, Nicolau JC. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial [Internet]. Circulation-cardiovascular interventions. 2018 ; 11( 6):[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084
Vancouver
Dillinger J-G, Nicolau JC. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial [Internet]. Circulation-cardiovascular interventions. 2018 ; 11( 6):[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084
Artigo de periodico
Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system (2018)
Bahia, Luciana R.; Santos, Raul D.; Araujo, Denizar V.; Rosa, Roger S.; Bahia, Luciana R.
Source: Archives of endocrinology metabolism. Unidade: FM
Subjects: PACIENTES INTERNADOS, CUSTOS DOS CUIDADOS DE SAÚDE, DOENÇAS CARDIOVASCULARES, HIPERCOLESTEROLEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BAHIA, Luciana R. et al. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. Archives of endocrinology metabolism, v. 62, n. 3, p. 303-308, 2018Tradução . . Disponível em: https://doi.org/10.20945/2359-3997000000030. Acesso em: 16 nov. 2024.
APA
Bahia, L. R., Santos, R. D., Araujo, D. V., Rosa, R. S., & Bahia, L. R. (2018). Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. Archives of endocrinology metabolism, 62( 3), 303-308. doi:10.20945/2359-3997000000030
NLM
Bahia LR, Santos RD, Araujo DV, Rosa RS, Bahia LR. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system [Internet]. Archives of endocrinology metabolism. 2018 ; 62( 3): 303-308.[citado 2024 nov. 16 ] Available from: https://doi.org/10.20945/2359-3997000000030
Vancouver
Bahia LR, Santos RD, Araujo DV, Rosa RS, Bahia LR. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system [Internet]. Archives of endocrinology metabolism. 2018 ; 62( 3): 303-308.[citado 2024 nov. 16 ] Available from: https://doi.org/10.20945/2359-3997000000030
Artigo de periodico
Management of cardiogenic shock complicating myocardial infarction (2018)
Mebazaa, Alexandre; Hajjar, Ludhmila Abrahao
Source: Intensive care medicine. Unidade: FM
Subjects: CHOQUE CARDIOGÊNICO, ESTUDOS RANDOMIZADOS, CUIDADOS CRÍTICOS, ANGIOPLASTIA TRANSLUMINAL PERCUTÂNEA CORONÁRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MEBAZAA, Alexandre e HAJJAR, Ludhmila Abrahao. Management of cardiogenic shock complicating myocardial infarction. Intensive care medicine, v. 44, n. 6, p. 760-773, 2018Tradução . . Disponível em: https://doi.org/10.1007/s00134-018-5214-9. Acesso em: 16 nov. 2024.
APA
Mebazaa, A., & Hajjar, L. A. (2018). Management of cardiogenic shock complicating myocardial infarction. Intensive care medicine, 44( 6), 760-773. doi:10.1007/s00134-018-5214-9
NLM
Mebazaa A, Hajjar LA. Management of cardiogenic shock complicating myocardial infarction [Internet]. Intensive care medicine. 2018 ; 44( 6): 760-773.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s00134-018-5214-9
Vancouver
Mebazaa A, Hajjar LA. Management of cardiogenic shock complicating myocardial infarction [Internet]. Intensive care medicine. 2018 ; 44( 6): 760-773.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s00134-018-5214-9
Artigo de periodico
Clinical Genetic Testing for Familial Hypercholesterolemia (2018)
Sturm, Amy C.; Santos, Raul D.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, DOENÇAS CARDIOVASCULARES, COLESTEROL, CUSTOS DOS CUIDADOS DE SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STURM, Amy C. e SANTOS, Raul D. Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 72, n. 6, p. 662-680, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.05.044. Acesso em: 16 nov. 2024.
APA
Sturm, A. C., & Santos, R. D. (2018). Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, 72( 6), 662-680. doi:10.1016/j.jacc.2018.05.044
NLM
Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
Vancouver
Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
Artigo de periodico
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2018)
Giugliano, Robert P.; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 16 nov. 2024.
APA
Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
NLM
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Vancouver
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Artigo de periodico
Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS) (2018)
Danchin, Nicolas; Santos, Raul D.
Source: European journal of preventive cardiology. Unidade: FM
Subjects: ESTATINAS, DOENÇAS CARDIOVASCULARES, COLESTEROL, LIPOPROTEÍNAS LDL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DANCHIN, Nicolas e SANTOS, Raul D. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). European journal of preventive cardiology, v. 25, n. 10, p. 1087-1094, 2018Tradução . . Disponível em: https://doi.org/10.1177/2047487318777079. Acesso em: 16 nov. 2024.
APA
Danchin, N., & Santos, R. D. (2018). Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). European journal of preventive cardiology, 25( 10), 1087-1094. doi:10.1177/2047487318777079
NLM
Danchin N, Santos RD. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS) [Internet]. European journal of preventive cardiology. 2018 ; 25( 10): 1087-1094.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1177/2047487318777079
Vancouver
Danchin N, Santos RD. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS) [Internet]. European journal of preventive cardiology. 2018 ; 25( 10): 1087-1094.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1177/2047487318777079
Artigo de periodico
Familial hypercholesterolaemia (2017)
Defesche, Joep C.; Gidding, Samuel S.; Harada-Shiba, Mariko; Santos Filho, Raul Dias dos; Wierzbicki, Anthony S.
Source: Nature reviews disease primers. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, COLESTEROL, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DEFESCHE, Joep C. et al. Familial hypercholesterolaemia. Nature reviews disease primers, v. 3, 2017Tradução . . Disponível em: https://doi.org/10.1038/nrdp.2017.93. Acesso em: 16 nov. 2024.
APA
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Santos Filho, R. D. dos, & Wierzbicki, A. S. (2017). Familial hypercholesterolaemia. Nature reviews disease primers, 3. doi:10.1038/nrdp.2017.93
NLM
Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/nrdp.2017.93
Vancouver
Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/nrdp.2017.93
Artigo de periodico
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD (2017)
Charytan, David M.; Burdmann, Emmanuel de Almeida
Source: American journal of kidney diseases. Unidade: FM
Subjects: FALÊNCIA RENAL CRÔNICA, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS, INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHARYTAN, David M. e BURDMANN, Emmanuel de Almeida. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, v. 70, n. 4, p. 522-531, 2017Tradução . . Disponível em: http://observatorio.fm.usp.br/handle/OPI/21785. Acesso em: 16 nov. 2024.
APA
Charytan, D. M., & Burdmann, E. de A. (2017). ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, 70( 4), 522-531. doi:10.1053/j.ajkd.2017.04.018
NLM
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 nov. 16 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785
Vancouver
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 nov. 16 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785
Artigo de periodico
Palliative care in interstitial lung disease: living well (2017)
Kreuter, Michael; Kairalla, Ronaldo Adib
Source: Lancet respiratory medicine. Unidade: FM
Subjects: QUALIDADE DE VIDA, CUIDADOS PALIATIVOS, DOENÇAS PULMONARES INTERSTICIAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KREUTER, Michael e KAIRALLA, Ronaldo Adib. Palliative care in interstitial lung disease: living well. Lancet respiratory medicine, v. 5, n. 12, p. 968-980, 2017Tradução . . Disponível em: https://doi.org/10.1016/S2213-2600(17)30383-1. Acesso em: 16 nov. 2024.
APA
Kreuter, M., & Kairalla, R. A. (2017). Palliative care in interstitial lung disease: living well. Lancet respiratory medicine, 5( 12), 968-980. doi:10.1016/S2213-2600(17)30383-1
NLM
Kreuter M, Kairalla RA. Palliative care in interstitial lung disease: living well [Internet]. Lancet respiratory medicine. 2017 ; 5( 12): 968-980.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/S2213-2600(17)30383-1
Vancouver
Kreuter M, Kairalla RA. Palliative care in interstitial lung disease: living well [Internet]. Lancet respiratory medicine. 2017 ; 5( 12): 968-980.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/S2213-2600(17)30383-1

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Date published

Subjects

Source title

Countries/Territories

Funding Agencies